Researchers Engineered Macrophages to Attack Solid Tumors
Scientists at the University of Wisconsin modified cells to ignore immune-evading signals from cancer.
Updated on Oct. 7, 2026 in Cancer
Live Poll
Should medical research prioritize new immunotherapy techniques to better treat difficult solid tumors?
University of Wisconsin researchers genetically modified macrophages to effectively target and destroy solid tumors. Published on October 7, 2026, the study demonstrates that removing specific signaling receptors allows these cells to bypass immune evasion.
Why it matters
Cancer cells often survive by hijacking natural wound-healing signals to prevent immune detection, a pathway known as the 'don't eat me' signal. By engineering macrophages to bypass this, scientists hope to provide a more effective way to treat aggressive solid tumors.
The study utilized induced pluripotent stem cells to generate macrophages with the SIRPalpha gene knocked out via CRISPR. These modified cells demonstrated enhanced tumor-killing capabilities when triggered by specific binding to cancer antigens.
The players
University of Wisconsin
This public research university served as the primary site where researchers developed the genetically modified macrophage therapy.
The details
Researchers removed the SIRPalpha gene to prevent macrophages from binding to the CD47 protein, which tumors use to signal that they should not be consumed. The modified macrophages also utilize an added CAR molecule or antibody to ensure they only attack specific, targeted tumor cells.
Timeline
October 7, 2026: The research findings were published.
The Big Picture
This research extends the success of CAR-T cell immunotherapy by applying similar engineering principles to macrophages to target solid tumors. By shifting the focus from T-cells to macrophages, scientists are addressing the distinct challenges posed by the microenvironment of solid cancers.
This breakthrough could eventually expand treatment options for patients with solid tumors like melanoma and ovarian cancer by bypassing immune evasion. While still in the preclinical stage, the research offers a potential pathway for more precise, targeted immune therapies.
The takeaway
By stripping away the receptor that cancer cells use to hide, scientists have created a more aggressive immune cell capable of recognizing hidden tumors. This approach could change how doctors engineer the body's own defenses to combat complex, solid-mass malignancies.
What happens next
The research team plans to conduct further studies to determine how to better support these modified macrophages within preclinical mouse models.
Further reading
Learn more about the latest advancements in Cancer research and emerging therapies.
Source note: This article includes information reported by The Badger Herald.
Live Poll
Should medical research prioritize new immunotherapy techniques to better treat difficult solid tumors?
